School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Department of Global Health, University of Washington, Seattle, WA, United States of America.
PLoS One. 2023 Jun 23;18(6):e0287525. doi: 10.1371/journal.pone.0287525. eCollection 2023.
Adolescent girls and young women (AGYW) in sub-Saharan Africa are disproportionately affected by the HIV epidemic and face an array of challenges using proven behavioral and biomedical prevention methods. To address the urgent need for expanding prevention options, we evaluated the baseline preferences of HIV prevention methods among participants enrolled in the MTN-034/REACH crossover trial along with their stated product preference prior to product initiation.
AGYW aged 16-21 years were enrolled at 4 study sites: Cape Town and Johannesburg, South Africa; Kampala, Uganda; and Harare, Zimbabwe and randomly assigned to the sequence of using oral PrEP and the dapivirine ring for 6 months each, followed by a choice period in which they could choose either product (or neither) for an additional six months. Eligible AGYW were HIV-negative, not pregnant and using effective contraception for at least two months prior to enrollment. Descriptive statistics were used to summarize demographic and behavioral data while multinomial analysis was used to determine predictors of stated product preference (ring or oral PrEP).
Of the 247 AGYW enrolled in REACH, 34% were aged 16-17 and 89% had a primary partner.The median age of sexual debut was 16 years and 40% had ever been pregnant. At screening, 35% of participants were diagnosed with a sexually transmitted infection (STI), 39% had an AUDIT-C score associated with harmful drinking and 11% reported intimate partner violence in the past 6 months. Overall, 28% of participants, had CESD-10 scores suggestive of depressive symptoms (≥12) in the past week. At baseline, similar proportions stated a preference for the ring and oral PrEP (38.1% and 40.5% respectively), with 19% of participants stating they preferred both products equally. Only study site was significantly associated with product preference (P<0.05) with AGYW from Johannesburg having higher odds of preferring the ring and those from Kampala having higher odds of preferring both options equally.
We successfully enrolled African AGYW with a clear unmet need for HIV prevention. The balanced preference between the two products suggests that multiple biomedical prevention options may be appealing to this age group and could address their prevention needs.
撒哈拉以南非洲的少女和年轻女性(AGYW)不成比例地受到艾滋病毒流行的影响,并且在使用经过验证的行为和生物医学预防方法方面面临一系列挑战。为了满足扩大预防选择的迫切需求,我们评估了参加 MTN-034/REACH 交叉试验的参与者中 HIV 预防方法的基线偏好,以及在开始使用产品之前他们对产品的偏好。
在四个研究地点(南非的开普敦和约翰内斯堡;乌干达的坎帕拉;和津巴布韦的哈拉雷)招募了年龄在 16-21 岁的 AGYW,并随机分配给使用口服 PrEP 和 dapivirine 环各 6 个月的顺序,随后是选择期,在此期间他们可以选择再使用六个月的任何一种产品(或都不使用)。符合条件的 AGYW 艾滋病毒阴性,未怀孕,并且在入组前至少两个月使用有效的避孕方法。使用描述性统计来总结人口统计学和行为数据,而使用多项分析来确定规定产品偏好(环或口服 PrEP)的预测因素。
在参加 REACH 的 247 名 AGYW 中,34%的人年龄在 16-17 岁,89%的人有主要伴侣。首次性行为的中位年龄为 16 岁,40%的人曾怀孕。在筛选时,35%的参与者被诊断患有性传播感染(STI),39%的人 AUDIT-C 评分与有害饮酒有关,11%的人报告在过去 6 个月内存在亲密伴侣暴力。总的来说,28%的参与者在过去一周内的 CESD-10 评分中表现出抑郁症状(≥12)。在基线时,对环和口服 PrEP 的偏好比例相似(分别为 38.1%和 40.5%),有 19%的参与者表示他们同样更喜欢两种产品。只有研究地点与产品偏好显著相关(P<0.05),约翰内斯堡的 AGYW 更有可能更喜欢环,而坎帕拉的 AGYW 更有可能更喜欢两者平等。
我们成功招募了非洲 AGYW,她们对 HIV 预防的需求明显未得到满足。两种产品之间的平衡偏好表明,多种生物医学预防选择可能对该年龄组有吸引力,并可以满足他们的预防需求。